Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Search publicationsPsilocybin studies
Explore psilocybin studies by research question and study design. Compare human trials, observational reports, reviews and preprints with source-linked evidence.
Free access · No subscription for research tools or data exports
Understand the different kinds of psilocybin study
Psilocybin studies include randomized human trials, observational reports, studies in healthy volunteers, animal and laboratory experiments, and registered trial plans. They answer different questions. A registered study establishes a research plan; an observational improvement does not by itself establish causation. A positive randomized endpoint still needs interpretation alongside the comparator, follow-up and adverse events.
Human clinical studies
Compare the selected depression and alcohol-use studies by population, treatment setting, primary endpoint and follow-up. Their findings concern the supervised interventions studied, not unrestricted use.
Compare selected findings and limitationsCurrent and recruiting studies
Use exact registry recruitment status to locate ongoing psilocybin clinical studies. Start and completion dates are registry facts; they do not establish efficacy, publication or personal eligibility.
Recruiting psilocybin studiesLaboratory and mechanism studies
Mechanistic and animal experiments can help formulate hypotheses. Their endpoints and populations differ from clinical outcomes, so they should not be presented as direct evidence of treatment effectiveness.
Explore mechanism-related literatureSee the MSCA psilocybin–telomere research story for a source-linked hypothesis and independent preclinical follow-up, with limitations. Available in 20 languages.
Reviews, protocols and preprints
Reviews synthesise existing work, protocols describe planned methods, and preprints have not been peer reviewed. Preserve these distinctions when building an evidence set.
Research reading checklistBrowse indexed psilocybin studies
4914 matching records; first 20 shown. Derived labels aid screening and need verification against the methods. Coverage is broad but not exhaustive.
Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurementPérez Rosal Sergio R., Faber Sonya C. · 2026-12-01 · Psychedelics · PublishedMindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery modelAlbertyn Christopher P., Richard Jérémie, Shore Ron, Carlson Linda E. · 2026-12-01 · Psychedelics · PublishedPupil-DLC: An open-source deep learning pipeline for scalable, marker-less tracking of pupil dynamics across conscious and unconscious states.Seyfourian P, Marks LC, Claar LD, Nahas Y, Keating M, Koch C, Rembado I · 2026-11-01 · Journal of neuroscience methods · PublishedChanges in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionKelly Carlton M., Fradet Mathieu, Bostian Catherine M., Donnelly Anna, Ellis Sara, Ostacher Michael, Aaronson Scott, Suppes Trisha · 2026-11-01 · Journal of Affective Disorders · PublishedPsilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trialSayali, C.; Weisman, E.; Barrett, F. S. · 2026-10-29 · medRxiv · PREPRINT (not peer reviewed)Multi-scale effects of single-dose psilocybin in the macaque brainWang J, Chen J, Sun W, Yang Z, Luo C, Yang F, Zhu Y, Wang H, Zhang X, Masthay J, Baek S, Li J, Zhuo Y, Wang X, Wu Y, Ma Y, Sun Q, Ji W, Chang S, Wang X, Zhu X, Hu J, Chen Y, Yuan T. · 2026-10-29 · Research Square · PREPRINT (not peer reviewed)Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseNational Institute on Aging (NIA) · 2026-10-29 · ClinicalTrials.gov · CLINICAL TRIALA Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.Psyence Australia Pty Ltd · 2026-10-29 · ClinicalTrials.gov · CLINICAL TRIALA Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionUniversity of Washington · 2026-10-29 · ClinicalTrials.gov · CLINICAL TRIALAn Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality DisorderUniversity of Chicago · 2026-10-29 · ClinicalTrials.gov · CLINICAL TRIALConnectedness as a candidate pathway linking psilocybin retreat experiences to sustained wellbeing: a prospective naturalistic studyÅkesson Maria, Granqvist Pehr, Johansson Robert, Gruneau Brulin Joel · 2026-10-28 · Frontiers in Psychiatry · PublishedHigh-Quality Genome Assembly and Transcriptomic Analysis Reveal Potential Pathways for Psilocybin Biosynthesis in Gymnopilus dilepisYao Sen, Liu Yuanyuan, Xia Weiwei, Xia Yue, Yang Kai, Li Hui, Xie Baogui · 2026-10-28 · Journal of Fungi · PublishedPsychedelic assisted psychotherapy (2020-2025): a scoping review of clinical evidence, mechanisms, safety, and ethicsNasiru Mohammed Abdullahi, Rashid Menhas, Patience Osose Nasir, Mohamed Goda Elbqry, Fatma Mohamed Elmansy, Saddam Ahmed Al-Ahdal, Ashwaq Hamad Ali Alshmirry, Azza Elsayed Abd Elfatah Arafat, Samia Eaid Elgazzar, Fatima Sayed Osman Ashmieg · 2026-10-27 · Frontiers in Psychology · PublishedPsychedelics and psychosis: A systematic review of recent-era studies (1984-2025).Reis JAS, Ueta LZ, Bouso JC, Hallak JEC, Dos Santos RG. · 2026-10-27 · Journal of psychopharmacology (Oxford, England) · PublishedMagic pathways: the genes and enzymes of psilocybin biosynthesis.Worbs J, Schäfer T, Seibold PS, Blei F, Werten S, Rupp B, Hoffmeister D. · 2026-10-27 · Microbiology and molecular biology reviews: MMBR · PublishedFeasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerYvan Beaussant, MD, MSci · 2026-10-27 · ClinicalTrials.gov · CLINICAL TRIALSafety, Efficacy, and Mechanisms of Psilocybin-assisted Acceptance and Commitment Therapy (PACT) in Treating Major Depressive Disorder (MDD) Among VeteransVA Office of Research and Development · 2026-10-26 · ClinicalTrials.gov · CLINICAL TRIALSubstantial Treatment-Seeking Interest, Narrow Eligibility: Diagnostic Heterogeneity and External Validity in the PRIDE Psilocybin Trial-Relevance to Precision PsychiatryInserra Antonio, Persico Luca, Rosati Arianna, Fabale Mara, Cavallotto Clara, D’Andrea Giacomo, Zoratto Francesca, Pettorruso Mauro, De Risio Luisa, Ventriglio Antonio, Bellomo Antonello, Nicolò Giuseppe, Martinotti Giovanni · 2026-10-26 · Behavioral Sciences · PublishedSingle Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial.Feifel D, Seynaeve M, Cubala WJ, Dunbar F, Gründer G, Dueñas Herrero RM, Hindocha C, Liknaitzky P, McGuigan SM, Mehta S, Pierce M, Repantis D, Roberts C, Wiegand F, Conley R. · 2026-10-26 · JAMA · PublishedSex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis.Frick A, Blest-Hopley G, Girn M, Erritzoe D, Nutt D, Carhart-Harris R. · 2026-10-26 · Psychopharmacology · Published
Research questions with source-linked context
Psilocybin studies for depressionPsilocybin and alcohol-use studiesTopics, selected reports and outcome measuresPublication trends and denominators
Publication dates, study dates and indexing dates may differ. Clinical trial registrations describe planned methods, while primary reports describe findings. Read the editorial policy for source tracking, corrections and classification limits.